Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer - 27/02/14

Doi : 10.1016/j.urology.2013.10.026

E. David Crawford ^a,^⁎ , Nelson N. Stone ^b, Evan Y. Yu ^c, Phillip J. Koo ^d, Stephen J. Freedland ^e, Susan F. Slovin ^f, Leonard G. Gomella ^g, E. Roy Berger ^h, Thomas E. Keane ⁱ, Paul Sieber ^j, Neal D. Shore ^k, Daniel P. Petrylak ^l
the
Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group^{^∗}
Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group, University of Colorado Hospital, University of Colorado at Denver, Aurora, CO
E. Roy Berger, MD
Oncology Consortium, Scottsdale, AZ

Raoul S. Concepcion, MD
Urology Associates, Nashville, TN

E. David Crawford, MD
University of Colorado, Denver-Aurora, CO

Stephen Freedland, MD
Durham VA and Duke University, Durham, NC

Jorge A. Garcia, MD
CCF/CWRU Lerner College of Medicine, Cleveland, OH

Leonard G. Gomella, MD
Thomas Jefferson University, Philadelphia, PA

Larry Karsh, MD
The Urology Center of Colorado, Denver, CO

Thomas E. Keane, MD
Medical University of South Carolina, Charleston, SC

Phillip J. Koo, MD
University of Colorado School of Medicine, Denver, CO

Daniel P. Petrylak, MD
Yale University Cancer Center, New Haven, CT

Neal Shore, MD
Carolina Urologic Research Center/Atlantic Urology Clinics, Myrtle Beach, SC

Paul Sieber, MD
Lancaster Urology, Lancaster, PA

Susan F. Slovin, MD, PhD
Memorial Sloan-Kettering Cancer Center, New York, NY

Nelson N. Stone, MD
Icahn School of Medicine at Mount Sinai, New York, NY

Evan Y. Yu, MD
Fred Hutchinson Cancer Research Center, Seattle, WA

^a University of Colorado, Denver-Aurora, CO
^b Icahn School of Medicine at Mount Sinai, New York, NY
^c Fred Hutchinson Cancer Research Center, Seattle, WA
^d University of Colorado School of Medicine, Denver, CO
^e Durham VA and Duke University, Durham, NC
^f Memorial Sloan-Kettering Cancer Center, New York, NY
^g Thomas Jefferson University, Philadelphia, PA
^h Oncology Consortium, Scottsdale, AZ
ⁱ Medical University of South Carolina, Charleston, SC
^j Lancaster Urology, Lancaster, PA
^k Carolina Urologic Research Center, Myrtle Beach, SC
^l Yale University Cancer Center, New Haven, CT

^∗Reprint requests: E. David Crawford, M.D., Department of Urology, University of Colorado, Denver-Aurora, CO 80045.

Abstract

Prostate cancer is often associated with metastases to bone and/or soft tissue. The progression to metastatic castrate-resistant prostate cancer is a seminal event in disease progression affecting treatment decisions. A multidisciplinary group was convened to review the currently available imaging guidelines for metastatic disease in prostate cancer and found no consensus on eligibility criteria, type of imaging modality, and the frequency of scanning for detecting metastatic disease. The aim of this review was to present the recommendations from the group to identify optimal strategies for early identification of metastases in patients with prostate cancer.

Le texte complet de cet article est disponible en PDF.

Plan

Review of Current Guidelines and Relevant Clinical Validation Studies

New Imaging Strategies

Recommendations From the Workshop

Recommendation: Eligibility Criteria and Frequency of Scanning

Recommendation: Imaging Modalities

Conclusion

Financial Disclosure: E. Roy Berger - Speaker Bureau: Dendreon, Janssen, Medivation/Astellas, Sanofi, Watson; E. David Crawford - Grant/Research Support: Ferring, Janssen, NCI; Consultant: Bayer, Dendreon, Ferring, Janssen; Stephen Freedland - Consultant: Amgen, Bayer, Dendreon, Janssen; Speaker Bureau: Dendreon; Leonard Gomella - Consultant: Astellas, Bayer, Dendreon, Ferring; Grant/Research Support: Janssen; Thomas Keane - Consultant: Dendreon, Ferring, Janssen, Endo; Speaker Bureau: Amgen, Endo, Ferring; Phillip Koo - Shareholder: Exelixis; Consultant: Bayer, Dendreon; Daniel Petrylak - Grant/Research Support: Dendreon, Sanofi, Progenics, Lilly, OncoGeneX, Rogosin Institute; Consultant: Bayer, Exelixis, Ferring, Millennium, Dendreon, Johnson and Johnson, OncoGeneX; Scientific Advisory Board: Bellicum, Egenix; Paul Sieber - Shareholder: Dendreon; Consultant: Bayer, Dendreon, Onyx; Paid Instructor: Dendreon, Janssen; Speaker Bureau: Ferring, Watson, Astellas, Janssen, Amgen, Dendreon, Bayer; Neal D. Shore - Consultant: Algeta, Amgen, Astellas, Bayer, BN ImmunoTherapeutics, Dendreon, Ferring, Janssen, Medivation, Millennium, Pfizer, Sanofi; Speaker Bureau: Amgen, Astellas, Bayer, Dendreon, Ferring, Janssen; Susan Slovin - Grant/Research Support: Astex Pharmaceuticals; Consultant: Dendreon; Nelson Stone - Consultant: Nihon Medi-Physics; Speaker Bureau: Amgen, Bayer; Evan Yu - Grant/Research Support: Dendreon; Consultant: Dendreon.

Export

Vol 83 - N° 3

P. 664-669 - mars 2014 Retour au numéro

Article précédent

Quality of Life and Health Status Among Prostate Cancer Survivors and Noncancer Population Controls
Lixin Song, Yingchun Ji, Mathew E. Nielsen

| Article suivant

Prospective Evaluation of Testosterone Fluctuations During a Transition of Therapy From Degarelix to Leuprolide in Patients on Androgen Deprivation Therapy
Jack M. Zuckerman, Gregg Eure, John Malcolm, Lilian Currie, Robert Given

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer - 27/02/14

Abstract

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL